Blueprint Medicines Corp - Company Profile
Powered by 
All the sales intelligence you need on Blueprint Medicines Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Blueprint Medicines Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Blueprint Medicines Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Blueprint Medicines Corp Catalyst Calendar
Proactively evaluate Blueprint Medicines Corp’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.
A sample of Blueprint Medicines Corp Catalyst Calendar data
| Event Date | Event Type | Company Name | Ticker Symbol | Drug Name | Therapy Area | Indication | Source Type |
|---|---|---|---|---|---|---|---|
| 19 Feb 2020 | GDCTWXYZ | Lorem | Lorem | Lorem | WXYZ | Planned | Lorem |
| 10 Jan 2020 | Phase III Trial Initiation | Blueprint Medicines Corp; Chugai Pharmaceutical Co Ltd; CStone Pharmaceuticals Co Ltd; F. Hoffmann-La Roche Ltd; Labcorp Drug Development | 2616; 4519; BPMC; ROG | pralsetinib | Oncology; Respiratory | Adenocarcinoma; Carcinomas; Germ Cell Tumors; Head And Neck Cancer; Lung Cancer; Lung Disease; Metastatic Lung Cancer; Nerve Sheath Tumor; Non-Small Cell Lung Cancer; Non-Small Cell Lung Carcinoma; Unspecified Respiratory Disorders | Clinical Trial Registry |
| 31 Dec 2019 | Phase II Trial Results | Blueprint Medicines Corp; Syneos Health Inc | BPMC; SYNH | avapritinib | Gastrointestinal | Systemic Mastocytosis | Insights |
| 30 Dec 2019 | Phase I/II Trial Initiation | Blueprint Medicines Corp; Catalent Inc; CStone Pharmaceuticals Co Ltd | 2616; BPMC; CTLT | fisogatinib; sugemalimab | Oncology | Hepatocellular Carcinoma; Liver Cancer; Metastatic Hepatocellular Carcinoma (HCC) | Clinical Trial Registry |
Feature
Catalyst Calendar provides forecasted drug development milestones within the Pharma industry including expected timing, expected outcomes and possible financial impacts.
Benefit
Access:
- Trial Events for trials conducted globally by a company, university, institute or CRO: Trial Initiation, Trial Completion, Trial Results
- Regulatory Events related to drug filings with regulatory bodies, approvals and commercial launches. This is covered for the US, EU and Japan
- Intellectual Property Events for patent and exclusivity expiry specific to the US, EU and Japan: Constraining Patent Expiry (US/EU/Japan), Drug Expiry (US/EU/Japan), Commercial Launch (US/EU/Japan)
Value
Proactively evaluate companies and catalyst impacts
Stay ahead of the competition & improve corporate planning
Bolster business development with timely opportunities
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer